RESEARCH ARTICLE

Trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in selected regions across Ghana [version 1; peer review: awaiting peer review]

Peter Kojo Quashie1,2, Joe Kimanthi Mutungi1, Francis Dzabeng1, Daniel Oduro-Mensah1,3, Precious C. Opurum1, Kesego Tapela1,3, Aniefiok John Udoakang1, WACCBIP COVID-19 Team, Ivy Asante4, Lily Paemka1,3, Frederick Kumi-Ansah5, Osbourne Quaye1,3, Emmanuela Amoako6, Ralph Armah7, Charlyne Kilba7, Nana Afia Boateng7, Michael Ofori8, George B. Kyei4,9, Yaw Bediako1,2, Nicaise Ndam10, James Abugri11, Patrick Ansah12, William K. Ampofo4, Francisca Mutapi13, Gordon A. Awandare1,3

1. West African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana
2. The Francis Crick Institute, London, NW1 1AT, UK
3. Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Accra, P O BOX LG54, Legon, Ghana
4. Department of Virology- Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
5. Department of Microbiology, Cape Coast Teaching Hospital, Cape Coast, Ghana
6. Department of Pediatrics, Cape Coast Teaching Hospital, Cape Coast, Ghana
7. Department of Internal Medicine, Surgery, Pediatrics and Emergency Medicine, Greater Accra Regional Hospital, Accra, Ghana
8. Immunology Department-Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
9. Medical and Scientific Research Directorate, University of Ghana Medical Centre, Accra, Ghana
10. UMR 216 MERIT-IRD, Université de Paris, Paris, France
11. Department of Applied Chemistry and Biochemistry, C.K. Tedam University of Technology and Applied Sciences, Navrongo, Ghana
12. Navrongo Health Research Centre, Navrongo, Ghana
13. NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA), and Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, UK

Abstract

Background: We set out to estimate the community-level exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Ghana.

Methods: Phased seroprevalence studies of 2729 participants at selected locations across Ghana were conducted. Phase I (August 2020) sampled 1305 individuals at major markets/lorry stations, shopping malls, hospitals and research institutions involved in coronavirus disease 2019 (COVID-19) work. The study utilized a lateral flow rapid diagnostic test (RDT) which detected IgM and IgG antibodies against SARS-CoV-2 nucleocapsid protein.

Results: During Phase I, 252/1305 (19%) tested positive for IgM or IgG
or both. Exposure was significantly higher at markets/lorry stations (26.9%) compared to malls (9.4%), with 41–60-year group demonstrating highest seropositivity (27.2%). Exposure was higher in participants with no formal education (26.2%) than those with tertiary education (13.1%); and higher in informally employed workers (24.0%) than those in the formal sector (15.0%). Results from phases II and III, in October and December 2020 respectively, implied either reduced transmissions or loss of antibody expression in some participants. The Upper East region showed the lowest seropositivity (2%). Phase IV, in February 2021, showed doubled seropositivity in the upper income bracket (26.2%) since August 2020, reflective of Ghana’s second wave of symptomatic COVID-19 cases. This suggested that high transmission rates had overcome the initial socioeconomic stratification of exposure risk. Reflective of second wave hospitalisation trends, the 21-40 age group demonstrated modal seropositivity (24.9) in Phase IV whilst 40-60 years and 60+ previously demonstrated highest prevalence.

**Conclusions:** Overall, the data indicates higher COVID-19 seroprevalence than officially acknowledged, likely implying a considerably lower-case fatality rate than the current national figure of 0.84%. The data also suggests that COVID-19 is predominantly asymptomatic COVID-19 in Ghana. The observed trends mimic clinical trends of infection and imply that the methodology used was appropriate.

**Keywords**
African COVID-19, SARS-CoV-2, Seroepidemiology, Community seroprevalence, serology, Ghana
Corresponding author: Gordon A. Awandare (gawandare@ug.edu.gh)

Author roles: Quashie PK: Formal Analysis, Investigation, Methodology, Project Administration, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Mutungi JK: Investigation, Project Administration, Validation, Writing – Original Draft Preparation; Dzabeng F: Data Curation, Formal Analysis, Software, Validation, Writing – Original Draft Preparation; Oduro-Mensah D: Investigation, Writing – Original Draft Preparation, Writing – Review & Editing; Opurum PC: Investigation, Project Administration; Tapela K: Investigation, Project Administration; Udoakang AJ: Investigation, Validation, Writing – Original Draft Preparation; Asante I: Investigation; Paemka L: Investigation; Kumi-Ansah F: Resources; Quaye O: Resources, Writing – Review & Editing; Amoako E: Investigation; Armah R: Resources; Kilba C: Investigation; Boateng NA: Resources; Ofori M: Investigation, Writing – Review & Editing; Kyei GB: Resources; Bediako Y: Investigation, Validation, Writing – Review & Editing; Ndam N: Funding Acquisition, Writing – Review & Editing; Abugri J: Investigation, Writing – Review & Editing; Ansah P: Investigation; Ampofo WK: Validation, Writing – Review & Editing; Mutapi F: Conceptualization, Writing – Review & Editing; Awandare GA: Conceptualization, Funding Acquisition, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This study was supported by the Wellcome Trust [107755], through a Wellcome Trust/African Academy of Sciences Developing Excellence in Leadership Training and Science (DELTAS) grant to GA [DEL-15-007]. The DELTAS Africa Initiative is an independent funding scheme of the AAS’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107755] and the UK government. The views expressed in this publication are those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. This work was also supported by the National Institute of Health Research (NIHR) global health research programme grants using UK AID from the UK Government for Tackling Infections to Benefit Africa (TIBA partnership, University of Edinburgh [16/136/33]; and the World Bank African Centres of Excellence grant to GA [WACCBIP-NCDs]. PKQ and YB are supported by Crick African Network Career Accelerator fellowships [CAN/A00004/1 and CAN/A00003/1, respectively]. The views expressed in this publication are those of the authors and not necessarily those of the funders.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Quashie PK et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Quashie PK, Mutungi JK, Dzabeng F et al. Trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in selected regions across Ghana [version 1; peer review: awaiting peer review] Wellcome Open Research 2021, 6:173 https://doi.org/10.12688/wellcomeopenres.16890.1
First published: 06 Jul 2021, 6:173 https://doi.org/10.12688/wellcomeopenres.16890.1
Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, in late 2019\(^{1}\). By April 20\(^{a}\), 2021 there were 141,058,320 coronavirus disease 2019 (COVID-19) SARS-CoV-2 reported infections with 3,015,314 associated deaths (case fatality ratio (CFR): of 2.1%) globally. Of these, 4,437,846 COVID-19 cases and 118,133 deaths (CFR: 2.7%), representing 3.07% and 3.85% of all reported global cases and deaths, were from the 55 African Union Member States\(^2\). Ghana, from the first two reported (imported) cases on March 12\(^{a}\) 2020, by April 16\(^{a}\) 2021 reported a cumulative total of 91,709 confirmed cases with 771 associated deaths (CFR of 0.84%) by this date\(^3\).

The current gold standard method for diagnosis of SARS-CoV-2 infection is by real-time reverse transcription polymerase chain reaction (RT-PCR), which detects viral nucleic acid sequences, and thus the virus, present in the upper respiratory tract (nasopharyngeal or oropharyngeal) swab samples\(^4,5\). Due to limited resources, tests are prioritised on symptomatic, severe, and/or suspected cases, and occasionally on contacts of confirmed cases. Common symptoms of SARS-CoV-2 infection include fever, dry cough, tiredness and sore throat with onset between 5 to 14 days after infection\(^6\). Approximately 80% of infected persons show mild or no symptoms\(^7\), however, pose a danger of unmitigated transmission and potential rapid rise in disease onset, severity and death\(^8\). Additionally, RT-PCR sensitivity may be affected by viral load, virus replication rate, ribonucleic acid (RNA) isolation method, and the source or timing of swab collection relative to disease stage\(^9\). This could lead to false negativity of about 20%\(^10\), indicating that actual infections may be higher than reported per test.

Rapid immunodiagnostic tests (RDTs) can be used to detect either SARS-CoV-2-expressed proteins (antigens) in respiratory tract samples (e.g., sputum, throat swab) or human anti-SARS-CoV-2 specific antibodies in blood or serum within minutes. Rapid antigen tests have utility for rapid detection of transmissible infections but have lower sensitivity than PCR-based methods\(^11\) and have become common for routine SARS-CoV-2 screening at ports of entry. Some RDTs also detect the presence of antibodies against SARS-CoV-2 in bodily fluids. These are useful for performing population level surveillance of viral exposure. Unlike antigen RDT’s which pick up active and often transmissible infection, antibody RDTs tend to pick up the evidence of previous or recent infection and cannot be used to detect active infection\(^12\). There are more than 280 Conformité Européenne-in vitro diagnostics (CE-IVD)-marked COVID-19 antibody detection RDT kits listed with the Foundation for Innovative Diagnostics (FIND)\(^13\). Currently, lateral flow immunoassays (LFIAs), chemiluminescence immunoassays (CLIA)s, or enzyme-linked immunosorbent assays (ELISAs) are commonly used for detection of SARS-CoV-2 IgM (Immunoglobulin M) and IgG (Immunoglobulin G) antibodies\(^14,15\). Similar to other infections, SARS-CoV-2 elicits an immune response\(^16\), and the presence of the virus-specific antibodies in blood indicates previous or current infection regardless of the presence or absence of symptoms\(^17,18\).

Generally, IgM or IgG are produced early and later in infection, respectively\(^19\). It is currently unknown how long SARS-CoV-2 IgM and IgG antibodies persist, however, seroconversion of IgM appears to peak simultaneously with IgG within 2 to 3 weeks after symptoms onset\(^18,19,20-24\).

In addition to retrospectively evaluating infection dynamics and the population disease burden, serology tests are useful for vaccine trials, therapeutic antibodies results analyses, and tests for individual and herd immunity. Antibody presence can also help identify COVID-19-recovered individuals and potential donors of convalescent plasma for immunotherapy of critically sick COVID-19 patients\(^25\). Some seroprevalence studies have used cross-sectional snapshots to evaluate community level exposure of SARS-CoV-2\(^26\) but to our knowledge, no single study has attempted to track the spatial-temporal dynamics of SARS-CoV-2 exposure in Africa. Ghana reported its first two (imported) cases on March 12\(^{a}\), 2020\(^2\). By April 4\(^{a}\), positive cases who had neither travel history nor known contact with confirmed cases, were detected, implying local transmission. This study sought to identify spatiotemporal trends of COVID-19 antibody seroprevalence in selected regions across Ghana, and to identify demographics at high risk of exposure.

Methods

Ethical approval

Procedures in this study conform with the Ghanaian Public Health Act, 2012 (Act 851) and the Data Protection Act, 2012 (Act 843). Ethical approval was received from the Ethics Board of the College of Basic and Applied Sciences, University of Ghana (ECBAS 063/19–20), and the Ethical Review Committee of the Ghana Health Service (GHS-ERC 011/03/20).

Study design

This study was a multi-site repeated observational cross-sectional study carried out over a period of 7 months from July 27, 2020 to February 26, 2021. Phase I was performed between 27 July and September 14, 2020 (designated August 2020), followed by additional phases in October 2020, December 2020 and February 2021 to identify changes from the initial rates observed at public places (extended data, Figure S1\(^27\)). For ease of reference in the text, and for site anonymity, the sites were assigned codes based on site type and risk factors: markets and lorry stations (ML), malls (M), research centres (R), hospitals (H) and generalised community screening (C). Generalised community screening included attendees at a concert since that reflected individuals who would be otherwise dispersed through the community. A research centre involved in mass COVID-19 testing and a COVID-19 treatment centre were given the respective codes, RC and HC. This study included individuals aged 4 years and above across all study sites. Participants with recorded temperature above 37.5°C were excluded. There was no prior advertisement of sampling locations so as to capture individuals who would normally be there, not those who were specifically interested in getting screened. During screening, the activity was advertised at the site by use of a banner and through initial engagement and verbal explanation of the study to random individuals.
present at the study locations. Sampling bias was further reduced by sampling at different types of public locations and at different healthcare/research institutes. Phase I participants were invited to volunteer for the study at two shopping malls, three major markets/lorry stations (ML1-3), two research institutes involved in COVID-19 work (R1) and COVID-19 testing (RC), and three major hospitals, one of which was a COVID-19 treatment centre (H1, H2, and HC). Testing tables were set up in high traffic areas with enough space to allow adherence to social distancing protocols for both the participants and the study team. Informed consent was obtained from all study participants.

Exposure to COVID-19 was detected using a strip-in-cassette lateral flow rapid diagnostic test kit which simultaneously detects IgM and IgG antibodies against SARS-CoV-2 antigens. Phase II screened participants at one market (ML4), one research centre (R1) and two hospitals (H1, H4) while Phase III screened participants at ML1 and across two towns in the Upper East Region (C1). During Phase IV, the exposure levels of upper-income earners were evaluated by screening at 2 malls (M1 and M3) and a repeat screening at H2. In addition, the exposure level in a small town (C3) in the Eastern Region, near Accra, was estimated. Screening at hospitals and research facilities included only staff members and their close contacts; patients at the hospitals were excluded from this study. All tests were performed on-site and participants were subsequently informed of their exposure status and counselled to adhere to COVID-19 mitigation protocols. When IgM was detected, participants were referred for a COVID-19 PCR test.

**Study sites**

Individuals were recruited from public places in Accra (National capital, where >50% of reported cases occur), Kasoa (a densely-populated town in the Central Region, and a COVID-19 transmission hotspot\(^2\), which shares a border with Accra), Cape Coast (Central Regional capital), Akropong (a small town in the Eastern Region, a 15-minute drive away from Accra), Navrongo (a small town in the Upper East Region, which hosts a public university and a government Health Research Centre) and Bolgatanga (the Upper East Regional capital) (Figure 1). Medical and research Staff were also screened at facilities across Accra and one in Cape Coast.

**Sampling and Sample size determination**

Given that there was no previous COVID-19 sero-epidemiological survey in Ghana prior to the start of this study, we assumed 15% seroprevalence, we estimated minimum sample size of 2612 with non-response rate of 20% for this study.

---

**Figure 1.** Map of Ghana showing study sites. Figure was generated using QGIS (QGIS Development Team, 2009. QGIS Geographic Information System. Open Source Geospatial Foundation. URL [http://qgis.org](http://qgis.org)).
Sample size, \( n = Z^2 \times P(1-P) \times d/(d \times P)^2 \)
Where \( n = \) Sample size
\( Z = Z \) statistic for a level of confidence,
\( P = \) expected prevalence and
\( d = \) precision (= 0.10)
\( n = 1.96^2 \times 0.15(1-0.15) / (0.10 \times 0.15)^2 = 2176.91 \)
20% non-response = (20/100 \times 2176.9) = 435.38
Estimated sample size = 435.38 + 2176.91 = 2612.28

Testing device
The ‘UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit’ (Catalogue# UNCOV-40, Lot Number 20200326) was registered with the Ghana FDA, and the kit validation report was submitted to the Ghana Food and Drug Authority (FDA). Validation exercise was done prior to this study. Briefly, sera from RT-PCR confirmed COVID-19 cases were used to evaluate several kits’ performance since there were no established SARS-CoV-2 antibody detection standards for use at the commencement of this study. This kit had a manufacturer-declared IgG sensitivity and specificity of over 98%. Using the Ghana Food and Drugs Authority (FDA) validation protocol, the UNSCIENCE kit demonstrated a sensitivity of 66% when tested using 100 Ghanaian convalescent COVID-19 patient sera (2–4 weeks after a PCR-positive result). We checked the existence of pre-existing cross-reactive antibodies using sera from 100 PCR-verified COVID-19 negative samples and obtained a specificity of 94%. In the validation exercises, when a test result was not obvious, at least 3 researchers validated the reading. In the rare case of an invalid test (no control line, or wrong location of bands), the test was repeated. A representative set of randomly chosen positive and negative test results are shown in the extended data (Figure S2). The kit was also adjudged to have a concordance of 72% with the WHO-recommended Wantai ELISA kit.

Data management and analysis
An adapted short questionnaire (see extended data) was administered to capture participant socio-demographic data, COVID-19 knowledge, attitudes and perceptions (KAP) and COVID-19 testing history during the study. The draft questionnaire was field tested in July 2020 at Greater Accra Regional Hospital among healthcare workers. This field test aimed to evaluate whether the questions were comprehensible by the interviewees and to ensure credible data was generated. The Cronbach’s alpha coefficient of the COVID-19 knowledge and prevention related questions was 0.88, indicating acceptable internal consistency. In the field the questionnaire was administered after informed consent and testing, but before obtaining of screening result.

The data collected, including the antibody test results were entered and managed using Research Electronic Data Capture suite (REDCap version 11.1.2). The data were cleaned by checking for completeness, duplication and consistency. Cleaned data were analyzed with Stata 16 (StataCorp, College Station, Texas, USA) and R/RStudio. GraphPad Prism version 8.0.1 was used for some additional analysis and generation of figures. Descriptive analyses were performed and univariate and multivariate logistic regression models were used to assess the association between seroprevalence and risk factors. Multivariable logistic models for seropositivity were obtained by using a backward stepwise procedure. Demographic variables that were associated with seropositivity at the \( P<0.25 \) level were included. The overall goodness of fit was assessed using the Wald statistic. Unadjusted and adjusted odds ratios with 95% confidence intervals (CI) were computed and presented as parallel dot plots with error bars. Statistical significance was inferred for \( p \)-values below 0.05.

Results
Study sites and participant characteristics
A total of 2729 participants were screened for this study (underlying data, extended data, Figure S1), including 1305 in Phase I (10 sites: August, 2020), 395 in Phase II (4 sites: October, 2020), 393 in Phase III (2 sites: December, 2020) and 636 in Phase IV (4 sites: February 2021). Altogether, four markets/lorry stations (ML-1 was visited twice), three malls (M1, twice), two research institutes (R, twice), two sets of small towns locations (C1 and C3) and four hospitals (H1 and H2, twice) were screened across all phases. During Phase III, 200 individuals were also screened from Navrongo and Bolgatanga in the Upper East Region (C1), which had the lowest reported COVID-19 cases in Ghana at the time the study began. Attendees (81) at a free Afrochella concert in Accra were also screened during Phase III (C2), potentially representing a general cross-section of the GAR population.

During Phase I, 946 individuals were sampled in public spaces, including 616 at markets/lorry stations and 330 at malls, while 359 were sampled in healthcare (254) and research (105) facilities (Table 1). There was a slightly higher number of female participants than males. The modal age range was 21–40 years, and over 40% of the participants had a tertiary education. Tertiary education was defined as having a post-secondary qualification such as a diploma, degree or above. Most respondents worked in the informal sector, with low or mid-level socioeconomic status. Over 90% of participants had good knowledge of COVID-19 symptoms, transmission routes and preventative measures (extended data, Figure S3). Such knowledge did not, however, correlate with participants’ seropositivity status or mask-wearing prior to recruitment. Only 7% of participants had previously received a COVID-19 PCR test (extended data, Figure S4). Similar participant characteristics were observed in Phases II, III and IV with smaller numbers of participants.

Anti-SARS-CoV-2 seropositivity in Phase I
In Phase I, SARS-CoV-2 IgG, IgM or both antibodies were detected in 19% of all participants (Figure 2A), with the highest rate amongst participants sampled in markets/lorry stations (27%). Among health workers, those at COVID-19 treatment/testing sites had higher exposure rates compared to their
Table 1. Socio-demographic characteristics of participants (N=2729).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Phase 1 (n=1305)</th>
<th>Phase 2 (n=395)</th>
<th>Phase 3 (n=393)</th>
<th>Phase 4 (n=636)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exposure risk groups</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shopping malls (M)</td>
<td>330</td>
<td>25.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Markets/Lorry stations (ML)</td>
<td>616</td>
<td>47.2</td>
<td>152</td>
<td>38.5</td>
</tr>
<tr>
<td>COVID testing/treatment centres (RC/HC)</td>
<td>105</td>
<td>8.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Health Research centres/Hospital R/H</td>
<td>254</td>
<td>19.5</td>
<td>243</td>
<td>61.5</td>
</tr>
<tr>
<td>Navrongo/Bolgatanga (C1)</td>
<td></td>
<td></td>
<td>200</td>
<td>63.5</td>
</tr>
<tr>
<td>Afrochella Concert (C2)</td>
<td></td>
<td></td>
<td>78</td>
<td>19.8</td>
</tr>
<tr>
<td>Akropong (C3)</td>
<td></td>
<td></td>
<td>199</td>
<td>31.3</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>591</td>
<td>45.3</td>
<td>124</td>
<td>31.4</td>
</tr>
<tr>
<td>Female</td>
<td>714</td>
<td>54.7</td>
<td>271</td>
<td>68.6</td>
</tr>
<tr>
<td><strong>Age group (in years)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;21</td>
<td>63</td>
<td>4.8</td>
<td>13</td>
<td>3.3</td>
</tr>
<tr>
<td>21–40</td>
<td>769</td>
<td>58.9</td>
<td>216</td>
<td>54.7</td>
</tr>
<tr>
<td>41–60</td>
<td>365</td>
<td>28.0</td>
<td>119</td>
<td>30.1</td>
</tr>
<tr>
<td>60+</td>
<td>89</td>
<td>6.8</td>
<td>13</td>
<td>3.3</td>
</tr>
<tr>
<td>Missing</td>
<td>19</td>
<td>1.5</td>
<td>34</td>
<td>8.6</td>
</tr>
<tr>
<td><strong>Educational level</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None/Basic</td>
<td>402</td>
<td>30.8</td>
<td>128</td>
<td>32.4</td>
</tr>
<tr>
<td>Secondary</td>
<td>245</td>
<td>18.8</td>
<td>54</td>
<td>13.7</td>
</tr>
<tr>
<td>Tertiary</td>
<td>616</td>
<td>47.2</td>
<td>133</td>
<td>33.7</td>
</tr>
<tr>
<td>Missing</td>
<td>42</td>
<td>3.2</td>
<td>80</td>
<td>20.3</td>
</tr>
<tr>
<td><strong>Employment type</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formal</td>
<td>520</td>
<td>39.8</td>
<td>171</td>
<td>43.3</td>
</tr>
<tr>
<td>Informal</td>
<td>655</td>
<td>50.2</td>
<td>175</td>
<td>44.3</td>
</tr>
<tr>
<td>Student</td>
<td>59</td>
<td>4.5</td>
<td>21</td>
<td>5.3</td>
</tr>
<tr>
<td>Unemployed</td>
<td>44</td>
<td>3.4</td>
<td>19</td>
<td>4.8</td>
</tr>
<tr>
<td>Missing</td>
<td>27</td>
<td>2.1</td>
<td>9</td>
<td>2.3</td>
</tr>
<tr>
<td><strong>Socio-economic status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowest</td>
<td>524</td>
<td>40.2</td>
<td>170</td>
<td>43.0</td>
</tr>
<tr>
<td>Middle</td>
<td>259</td>
<td>19.8</td>
<td>122</td>
<td>30.9</td>
</tr>
<tr>
<td>Higher</td>
<td>522</td>
<td>40.0</td>
<td>103</td>
<td>26.1</td>
</tr>
</tbody>
</table>

Wellcome Open Research 2021, 6:173 Last updated: 10 JUL 2021
colleagues who were not directly handling COVID-19 patients or samples. There was no significant difference in seropositivity across genders (Figure 2B). When stratified by age categories, the highest level of seroprevalence (27.1%) was observed in the 41–60 years age group (Figure 2C). Participants with higher educational backgrounds (Figure 2D), those employed in the formal sector (Figure 2E) and those with higher economic standing (Figure 2F) had lower exposure levels than participants with lower educational background, informal sector workers and poor economic background. Only 20.9% of seropositive participants reported having had COVID-19-like symptoms (Figure 3).

Logistic regression analysis was performed on data from Phase I to identify factors that correlated with increased risk of SARS-CoV-2 exposure (Figure 4). Univariate modelling showed that socio-demographic factors were significantly associated with increased or decreased exposure. These were: being sampled at either markets and lorry stations (Odds ratio, OR: 3.6, 95% confidence interval, CI: 2.4-5.4, p<0.001) or a COVID-19 treatment/testing centre (OR: 2.4, 95% CI:1.3-4.4, p< 0.004), being employed in the informal sector (OR: 1.8, 95% CI:1.3-2.4, p<0.001) having a high education (OR: 0.4, 95% CI:0.3-0.6, p<0.001) or having a high income (OR:0.6, 95% CI:0.5-0.9, p<0.005). In a multivariate model, sampling location, participant educational level and income/socioeconomic status remained significantly associated with COVID-19 exposure.

Figure 2. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity reported by (A) Sampling sites, (B) gender, (C) Age, (D) Highest education level, (E) Employment status and (F) Socioeconomic status. Error bars reflect the standard error of measurement. Where relevant, p-values are indicated as follows p<0.05; *,p<0.01;**, p<0.001; ***. Error bars, where relevant, represent standard deviation across sites. COVID-19=coronavirus disease 2019.

Figure 3. Presence of two or more self-reported coronavirus disease 2019 (COVID-19) symptoms in seropositive individuals in the month preceding the study.
status; participants were significantly more likely to have COVID-19 antibodies if they were sampled in markets/lorry stations (adjusted odds ratio, aOR: 2.5, 95% CI: 1.5-4.2, p<0.001), and COVID-19 testing/treatment centre (aOR:3.6, 95% CI:1.7-7.5, p<0.001).

Phases II and III: Targeted follow-up seroprevalence surveys
As follow-ups to Phase I, the trend of population seroprevalence was again investigated in Phase II and III. Two months after the initial public places screening (October 2020), 144 individuals were screened at a lorry station in Accra and 212 participants at two hospitals in Accra and Cape Coast. Overall, seroprevalence at the lorry station was 19.7%, and 13% at the two hospitals. The H4 facility staff had higher (18.5%) seroprevalence level than those at H1, previously sampled in Phase I. A Phase III screening exercise was conducted at M1, which was originally sampled in Phase I, and that showed an estimated seroprevalence of 23.5%. Additionally, 200 individuals were screened in the Upper East Region (C1), an area with low population density and very few reported COVID-19 cases at the time. Here, 4 out of 200 individuals (2%) tested positive for SARS-CoV-2 antibodies (Table 2). Individuals screened at the Afrochella concert (C2) showed an estimated seroprevalence of 16%, which was similar to the Phase I data, with the HC site excluded.

Phase IV: Impact of the second wave
Beginning in late December 2020, large numbers of symptomatic COVID-19 cases started to be detected at hospitals and treatment centres in Accra and other major cities. The patients were mostly of high socio-economic standing. We therefore performed repeat screening at M1 and H2 (both sampled in Phase I) and sampled again at M3 and a small town in the Eastern Region (C3). The average seroprevalence at the two malls (M1 and M3) was at 27%, whilst H1 and C3 recorded 25% and 17% respectively.

Discussion
This study was necessitated by a dearth of epidemiological data on COVID-19 prevalence in Ghana. In the first few months of the pandemic when prevalence was low, Ghana ranked high among African countries, and even globally, for administering high numbers of tests per million people. To meet the high demand for testing, Ghana’s main testing centre, Noguchi Memorial Institute for Medical Research, employed “sample pooling” methods. However, since then, Ghana has declined significantly to number 22 in tests per million of population. Data from the Ghana Health Service’s COVID-19 archives indicates that testing has significantly reduced after peaking in June, correlating with a drop in daily reported cases. Among other factors, the reduced testing could be due to...
Table 2. Summary of participant’s seropositivity status (N=2729).

<table>
<thead>
<tr>
<th>Sampling location (Code)</th>
<th>August 2020 (n=1305)</th>
<th></th>
<th>Oct 2020 (n=395)</th>
<th></th>
<th>Dec - 2020 (n=393)</th>
<th></th>
<th>Jan- Feb 2021 (n=636)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Antibody Positivity</td>
<td>Number</td>
<td>Antibody Positivity</td>
<td>Number</td>
<td>Antibody Positivity</td>
<td>Number</td>
<td>Antibody Positivity</td>
</tr>
<tr>
<td>Shopping malls (M)</td>
<td>330</td>
<td>9.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>356</td>
<td>25.3</td>
</tr>
<tr>
<td>Markets/Lorry stations (ML)</td>
<td>616</td>
<td>26.9</td>
<td>152</td>
<td>19.7</td>
<td>115</td>
<td>23.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID testing/treatment Centres (RC/HC)</td>
<td>105</td>
<td>20.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Research Centres/Hospital (R/H)</td>
<td>254</td>
<td>13.4</td>
<td>243</td>
<td>14.0</td>
<td></td>
<td></td>
<td>81</td>
<td>22.2</td>
</tr>
<tr>
<td>Navrongo/Bolgatanga (C1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>200</td>
<td>2.0</td>
</tr>
<tr>
<td>Afrochella Concert (C2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>78.0</td>
<td>15.4</td>
</tr>
<tr>
<td>Akropong (C3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>199</td>
<td>18.6</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>591</td>
<td>18.1</td>
<td>124</td>
<td>14.5</td>
<td>131</td>
<td>1.7</td>
<td>10.7</td>
<td>22.7</td>
</tr>
<tr>
<td>Female</td>
<td>714</td>
<td>20.3</td>
<td>271</td>
<td>17.0</td>
<td>184</td>
<td>2.8</td>
<td>11.1</td>
<td>22.9</td>
</tr>
<tr>
<td><strong>Age group (in years)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4–21</td>
<td>63</td>
<td>17.5</td>
<td>13</td>
<td>0.0</td>
<td>63</td>
<td>11.1</td>
<td>44</td>
<td>9.1</td>
</tr>
<tr>
<td>21–40</td>
<td>769</td>
<td>16.1</td>
<td>216</td>
<td>11.1</td>
<td>251</td>
<td>11.6</td>
<td>362</td>
<td>24.9</td>
</tr>
<tr>
<td>41–60</td>
<td>365</td>
<td>27.1</td>
<td>119</td>
<td>21.8</td>
<td>57</td>
<td>10.5</td>
<td>167</td>
<td>22.8</td>
</tr>
<tr>
<td>60+</td>
<td>89</td>
<td>18.0</td>
<td>13</td>
<td>38.5</td>
<td>7.0</td>
<td>14.3</td>
<td>62</td>
<td>21.0</td>
</tr>
<tr>
<td>Missing</td>
<td>19</td>
<td>10.5</td>
<td>34</td>
<td>26.5</td>
<td>15</td>
<td>0.0</td>
<td>1</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Educational level</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None/Basic</td>
<td>402</td>
<td>26.6</td>
<td>128</td>
<td>22.7</td>
<td>117</td>
<td>12.0</td>
<td>202</td>
<td>17.8</td>
</tr>
<tr>
<td>Secondary</td>
<td>245</td>
<td>24.5</td>
<td>54</td>
<td>14.8</td>
<td>148</td>
<td>11.5</td>
<td>139</td>
<td>25.9</td>
</tr>
<tr>
<td>Tertiary</td>
<td>616</td>
<td>13.5</td>
<td>133</td>
<td>15.0</td>
<td>106</td>
<td>10.4</td>
<td>279</td>
<td>24.7</td>
</tr>
<tr>
<td>Missing</td>
<td>42</td>
<td>4.8</td>
<td>80</td>
<td>8.8</td>
<td>22</td>
<td>4.5</td>
<td>16</td>
<td>25.0</td>
</tr>
<tr>
<td>Month</td>
<td>Number Sampled</td>
<td>Number Antibody</td>
<td>Antibody Positivity %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>----------------</td>
<td>-----------------</td>
<td>-----------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>August 2020</td>
<td>520</td>
<td>15.0</td>
<td>23.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct 2020</td>
<td>655</td>
<td>24.0</td>
<td>24.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dec 2020</td>
<td>259</td>
<td>16.9</td>
<td>12.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan-Feb 2021</td>
<td>44</td>
<td>9.1</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Socio-economic status</td>
<td>Number Sampled</td>
<td>Number Antibody</td>
<td>Antibody Positivity %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>524</td>
<td>23.1</td>
<td>18.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Middle</td>
<td>259</td>
<td>19.7</td>
<td>25.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>522</td>
<td>15.3</td>
<td>26.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG</td>
<td>13.0</td>
<td>15.2</td>
<td>15.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgM</td>
<td>1.6</td>
<td>2.3</td>
<td>2.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
the fact that at the current positivity rate of 8.3% of tested cases, sample pooling is no longer a viable cost-cutting and test-rate enhancing measure. The seroprevalence rate average of 19.3% obtained from our public screening exercises is probably a better reflection of SARS-CoV-2 infections in Ghana, especially in the large and densely populated urban areas. Additionally, currently, most RT-PCR tests in the country are administered to travellers, representing a higher economic tier of society. The relatively low (9.3%) seroprevalence initially observed in malls, assumed to be frequented by the higher tiers of society, may correlate well with the official 10% RT-PCR test positivity rate reported in September 2020[^1].

Participants across all sites demonstrated good knowledge of COVID-19 risks, symptoms and preventive measures. This did not however translate into observation of protocols in the markets and lorry stations, where, by visual estimation, 10–50% of the study participants arrived mask-less and had to be requested to wear a mask donated by the study. This attitude corresponds with two surveys on mask-wearing, carried out by the Ghana Health Service which showed public mask wearing of ~40% and 10% in July and September, respectively[^5,6]. Our previous genomic study showed evidence of undetected community spread likely caused by asymptomatic individuals[^7]. Of note, nearly 80% of people who were seropositive did not report significant COVID-19 symptoms (Figure 3), confirming that SARS-CoV-2 infections in Ghana are predominantly asymptomatic, consistent with reported global trends[^8]. With the 19.3% seroprevalence in the Greater Accra Region (GAR), we inferred that nearly 1 million out of the estimated 5 million GAR residents may have already been exposed to SARS-CoV-2. This staggering number suggests that the actual fatality rate of COVID-19 in Ghana may be much lower than the reported CFR of 0.84%, since that would have translated to approximately 8000 deaths in a large metropolis like Accra, which would have been rather very obvious. Additionally, there was no evidence of a stressed or panicked healthcare system nor visible or anecdotal evidence of excess deaths during the Phase I hospital screening.

Given the higher-than-expected seroprevalence observed in the Greater Accra Region, follow-up surveys were conducted at some of the Phase I locations as well as other parts of the country to confirm the findings and obtain vital information about infection dynamics over time. Repeated screening of markets and lorry stations in October and December yielded seroprevalence rates of 19.7% and 23.5%, respectively. The seeming plateau in seroprevalence in lower socioeconomic status individuals may be indicative of, either a peaking of infections coincident with the onset of Phase I seroprevalence[^1], or loss of antibody expression in some section of the population over time. Phase II surveys at the health and research facilities which were not directly handling patients or testing samples, in October, also showed a similar overall seroprevalence (13%), as observed in August. Participants in Navrongo and Bolgatanga in the Upper East region (C1), with some of the lowest reported cases, showed very low (2%) seroprevalence, confirming the reliability of this study. Consistent with global reports, participants in the 40–60 and 60+ year age groups exhibited the highest seroprevalence levels across all 3 phases (Figure 4, extended data Figures S4, S5[^7]). The results of Phase IV reflected the high levels of new COVID-19 cases and hospitalisations in Ghana, mainly in the middle socioeconomic class[^8]. As such, it was not surprising that the socioeconomic divide in prevalence observed in Phase I had mostly disappeared and even appeared reversed by Phase IV. Importantly, Phase IV was the first time the modal surveyed age group (21–40) also demonstrated model seropositivity (24.9%). This trend mimicked hospitalisation and test positivity records since December 2020[^1].

Our observed seropositivity rates are in line with previous reports from other African countries[^17,41]. A study in Kenya estimated 20% SARS-CoV-2 seropositivity in adults (~1.6 million people) at a time when the total reported infections were 2093 (with approximately 90% asymptomatic cases) and 71 deaths of all ages[^9]. The initial trend relating income disparity and COVID-19 seropositivity is not surprising. Even in countries where lower seroprevalence was reported, such as China (1.63%), lower income status correlated with the highest seroprevalence (5.62%)[^10], and this trend was initially reflected in this current study. The shift to high prevalence even in high socioeconomic brackets is likely due to poor adherence to COVID-19 protocols during the period of this study, likely due to election activities[^11] and the 2020 Christmas/2021 New Year holiday festivities.

**Strengths and limitations of this study**

By surveying participants at different sites and times, representing categories of different perceived risk factors, this study obtained credible estimates for population-level prevalence across these sites and how that changed over the sampling period. This will allow future screening at these sites to determine the seroprevalence trends. However, most seroprevalence studies only reflect past disease burden. Using Markets and Lorry Stations enabled sampling of a broad cross-section of the Ghanaian populace.

Phase I of the study was conducted in the region with the greatest burden of reported infections and it was expected that a country-wide survey would yield less seroprevalence. Site H3, situated in the town of Cape Coast, a tourist hub and Central regional capital, exhibited a very high prevalence at 18.5% during Phase II, but this was not surprising given that M4, located in Kasoa, also in the Central Region, exhibited an exposure rate of 28% during Phase I. The low seroprevalence observed at C1 (2%) during Phase III hinted that community size/density may play a role in COVID-19 transmission. Given the geographical remoteness of C1 to the major hotspots of Accra and Kumasi, another small community (C3) in the country’s Southern belt with higher population density was screened, yielding an observed prevalence rate of 17%, and showing that SARS-CoV-2 exposure is not just a metropolitan burden, but one that needs to be tracked across the country. This, however, does not rule out that towns with lower population densities and who are far from metropolitan areas may exhibit lower seroprevalence levels.
During validation, this kit showed a sensitivity of 66%, when compared to PCR positivity. This is despite the manufacturer reporting sensitivity and specificity values above 98%. The apparent lower than expected sensitivity observed in local validation could at least partly be due to weak or delayed antibody responses in some of the infected persons. The import of this is that the seroprevalence levels reported in this study are likely underestimates of true disease prevalence.

One oft-repeated concern with SARS-CoV-2 seroprevalence studies in Africa is cross-reactivity due to pre-existing antibodies to other viruses and vaccines. Some studies have reported extensive cross-reactivity against SARS-CoV-2 in Africa. However, most of these studies had limitations, and as such their conclusions are unreliable. These flaws include extremely small study sizes (below 500 and even sometimes below 100), tend to be based at single institutions and/or cities and use samples collected at widely divergent time periods for their ‘Western’ and ‘African’ pre-COVID-19 samples. The UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit used in our study exhibited 94% specificity during validation (with plasma from 100 COVID-19 PCR-negative individuals). Antibody RDTs are contraindicated in cases of active fever, based on manufacturer’s information leaflets, unpublished analyses and other studies. We confirmed that none of the study respondents had temperature above 38, thereby reducing the likelihood of fever affecting the results.

Antibody cross-reactivity with other pathogens is often manifested in IgM detection. During validation, and in the field, detection of IgM was uncommon, and when detected, IgM was often accompanied by IgG. This reduced the likelihood that those IgM detections were as a result of cross-reactivity. That said, a cross-reactivity rate of 6% with IgM was detected during validation. However, the test kit performed even better in the field; Navrongo and Bolgatanga in the Upper-East region of Ghana are towns with populations highly vaccinated against other pathogens, yet only 2% of 200 individuals (4 individuals) showed seropositivity in this study. This low seropositivity correlated well with the low level of reported COVID-19 in those towns at the time and hinted that the rates observed in Accra and environs were due to the SARS-CoV-2 exposure rate, but not from cross-reactivity. Taken together, there is a low likelihood that cross-reactive antibodies played a significant role in this study.

**Conclusions and recommendations**

This study highlights a relatively high level of SARS-CoV-2 infections in the Greater Accra, Central and Eastern Regions, but not in the Upper East region. Most of these infections were unreported and likely asymptomatic.

Large scale cross-sectional studies of seroprevalence across Ghana and West Africa may be a practical approach for disease tracking even as vaccines are being deployed. The dynamism observed in demographic exposure risk over time highlights the need for continuous risk and prevalence assessments to track highly transmissible disease agents like SARS-CoV-2.

Finally, resources should be mobilised to research the molecular and immunological mechanisms underlying the apparent high tolerance to COVID-19 observed in Ghana, the West African sub-region, and Africa as a whole.

**Data availability**

Underlying data

Figshare: Underlying Data_Seroprevalence in Ghana.


Extended data


https://doi.org/10.6084/m9.figshare.14528823.

This project contains the following extended data:
- SeroprevalenceSupplFigs_20210503.pdf (Supplementary Figures 1–6)

Figshare: WACCBIP Seroprevalence in Ghana questionnaire.


This project contains the following extended data:
- COVID_seroprev_Questionnaire_WelcomeManuscript.docx (Questionnaire)

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

**Consent**

In line with the ethical protocol above, written informed consent was obtained for all study participants. Upon consent, each participant was assigned a unique identification number (ID). This ID was used for testing and data recording, thereby delinking participant identification with the test results and questionnaire answers. All consent forms are kept in a locked cabinet accessible to only the study PI and the WACCBIP Data Manager.

**Acknowledgements**

With their confirmed permission we are sincerely grateful to other WACCBIP COVID-19 Team members (WCT): Kyewewaa Boateng, Sylvester Languon, Jerry Quaye, Aaron Adom Manu, Eugene Boateng, Daniel Lorlorson Okpahal, Louisa Baaba Obeng, Oforiwa Ofori, Peggy...
36. GraphPad: GraphPad Software. 2020. Reference Source

References
38. 3news.com: Many of Covid-19 cases still among the middle, upper middle class – GHS. 2021.
Reference Source

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

42. Pilla V: Coronavirus pandemic: 'Pool testing' for COVID-19 may benefit India as US study proves test feasibility, efficacy. 2020.
Reference Source

PubMed Abstract | Publisher Full Text | Free Full Text

44. Worldometer: Coronavirus Update (Live). 2020; [cited 2021 February 2].
Reference Source

PubMed Abstract | Publisher Full Text | Free Full Text

Reference Source

Reference Source

P Tud Med Abstract | Publisher Full Text | Free Full Text

P tud Med Abstract | Publisher Full Text | Free Full Text

P tud Med Abstract | Publisher Full Text | Free Full Text

Reference Source

P tud Med Abstract | Publisher Full Text | Free Full Text

P tud Med Abstract | Publisher Full Text | Free Full Text

P tud Med Abstract | Publisher Full Text | Free Full Text

P tud Med Abstract | Publisher Full Text | Free Full Text

P tud Med Abstract | Publisher Full Text | Free Full Text